Trump Administration Unveils Head Start Overhaul, Promising $2.2 Billion in Savings and Room for 268,000 More Kids
The Trump administration announced a sweeping overhaul of Head Start this week, stripping away a wide range of federal regulations governing the decades-old early education program in a move officials say will free up $2.2 billion and open enrollment to as many as 268,000 additional children — even as some early childhood advocates warn the changes could weaken protections for the country’s most vulnerable kids. The Core of the Plan The proposal, unveiled by the Department of Health and Human Services, would eliminate many of the federal rules that have long governed how local Head Start centers operate, shifting significant authority to states and local program administrators instead. The centerpiece of the savings comes from a sharp cut to allowable administrative overhead, dropping the cap from 15% to just 5% — a change officials project will unlock the bulk of the $2.2 billion in projected savings, which the administration says will be reinvested directly into expanding the program rather than diverted elsewhere. Alex Adams, who leads the Administration for Children and Families within HHS, framed the changes as empowering local decision-makers rather than stripping away necessary safeguards. “If their structure is working for their community and their governing board and the parents who sit on that affirm that, no changes will be needed,” Adams told reporters, emphasizing that centers retain the option to keep operating exactly as they have been if that’s what works for their community. Not a Pure Deregulation Story Notably, the proposal isn’t simply about cutting rules — it adds new requirements in at least two areas. The administration is introducing enhanced nutrition standards championed by HHS Secretary Robert F. Kennedy Jr., along with a new physical activity mandate requiring 30 minutes of physical activity for every 3.5 hours of classroom instruction. HHS Secretary Kennedy struck a notably protective tone about the program’s mission despite the broader deregulation push. “It’s a program that works for the most vulnerable, of course, kids in our society,” Kennedy told reporters. “And it’s really important we protect it.” The Case for Deregulation Supporters of the plan point to a simple comparison: state-level childcare licensing standards, which apply to the vast majority of non-Head Start preschool and daycare programs nationwide, are far less restrictive than what Head Start currently requires — and those state standards still focus on the fundamentals of keeping children healthy and safe. In Mississippi, for example, one Head Start teacher is currently permitted to supervise only up to four two-year-olds, while ordinary state childcare rules would allow that same teacher to supervise up to a dozen. Administration officials argue that gap has made Head Start increasingly expensive to operate relative to its private-sector alternatives, contributing to a decade-long enrollment decline as programs have been forced to scale back the number of children they can serve under current federal funding levels. From that vantage point, freeing up billions in administrative savings to reinvest directly into serving more children isn’t a step backward for a program meant to help disadvantaged kids — it’s arguably the most direct way to actually grow it after years of shrinking enrollment driven by costs outpacing federal support. Where the Concerns Lie Early childhood policy researchers have raised concerns that loosening federal standards could undercut Head Start’s longstanding reputation as, in their view, the gold standard for early childhood education quality. Advocates within the Head Start community have also expressed skepticism that deregulation alone will meaningfully reverse the program’s decade-long enrollment slide, since the underlying cost pressures driving programs to scale back may not disappear simply because administrative requirements have eased. Context: A Program Under Repeated Scrutiny This isn’t the first time the Head Start program has faced upheaval under the current administration. Earlier this year, a leaked administration budget document proposed eliminating Head Start’s funding entirely, a plan that was ultimately abandoned after significant public backlash. Since then, the administration has also moved to roll back a Biden-era plan to raise wages and benefits for Head Start workers, briefly attempted to freeze program funding altogether before rescinding that order, and moved to restrict eligibility based on immigration status — a change that was temporarily blocked by a federal judge. The administration has also consolidated the program’s regional offices, a reorganization that led to layoffs among Head Start staff. Head Start has historically enjoyed bipartisan support since its creation, and currently serves roughly 700,000 of the nation’s most vulnerable children nationwide, including kids who are homeless, in foster care, or living with disabilities. What Happens Next The proposed rule was formally posted for public comment this week, giving Americans 60 days to weigh in before any changes could take effect. Given the scope of the overhaul and the program’s history of drawing legal challenges over previous policy changes, further litigation attempting to delay or block implementation appears likely regardless of how the public comment period plays out. This story is developing.
Senate Committee Holds Fauci in Contempt After He Invokes the Fifth More Than 100 Times
A Senate committee voted along party lines Thursday to hold Dr. Anthony Fauci in contempt of Congress, after the former NIAID director refused to answer lawmakers’ questions about the government’s handling of COVID-19 and the pandemic’s origins at a hearing just one week earlier — a defiant stance that even members of his own legal team acknowledged put him on shaky procedural ground. What Happened at the Hearing Fauci, who once led the National Institute of Allergy and Infectious Diseases, appeared before the Senate Homeland Security and Governmental Affairs Committee on July 29, where he invoked his Fifth Amendment right against self-incrimination more than 100 times rather than respond to lawmakers’ questions. Republicans on the committee noted what they characterized as a contradiction: Fauci delivered opening testimony addressing the pandemic response, then declined to answer virtually any follow-up questions on the same subject matter. The Contempt Vote The committee voted 8-5 along party lines Thursday to advance the contempt resolution. Chairman Sen. Rand Paul, R-Ky., framed the vote narrowly, insisting it wasn’t about relitigating Fauci’s pandemic-era policy decisions but purely about whether a witness can defy a direct order to answer questions without consequence. “We are voting on whether a witness who has received the benefit of a sweeping federal pardon can be ordered by this committee to answer questions and then defy that order without consequence,” Paul said ahead of the vote. That pardon reference is central to Republicans’ argument. Fauci received a broad federal pardon in early 2025, and Paul and other committee Republicans argue that a pardon covering past conduct shouldn’t shield him from having to testify about that same conduct now — nor should it protect him from consequences for any false statements made during current testimony, since a pardon can’t retroactively cover perjury committed after the fact. Democrats Push Back, Question the Point Democrats on the committee, led by Sen. Gary Peters, D-Mich., attempted to table the contempt vote before it proceeded, arguing the whole exercise was symbolic and wouldn’t actually accomplish anything. “This resolution will not provide the committee with any additional information, or compel Dr. Fauci to provide answers to our inquiries,” Peters said. “Criminal contempt is punitive; it does not compel a witness to answer questions or produce the documents we’d all like to see.” Paul rejected the tabling motion, telling Democrats their effort to delay the vote was “intended to avoid accountability.” Fauci’s legal counsel, David Schertler, was similarly dismissive of the proceeding, calling Thursday’s vote “a crude political stunt.” What Happens Next Under normal procedure, a contempt resolution that clears committee would move to a vote on the full Senate floor, where it would need 60 votes to pass — a threshold this measure is highly unlikely to clear given the chamber’s makeup. Rather than send it there and watch it fail, Paul said he intends to refer the matter directly to the Department of Justice, leaving it up to federal prosecutors to decide whether to pursue the case. If prosecutors move forward, the matter would go to the U.S. Attorney for the District of Columbia, Jeanine Pirro, who could ultimately bring it before a grand jury. The Bigger Picture The vote is the latest chapter in a yearslong effort by congressional Republicans to hold Fauci accountable for decisions made during the COVID-19 pandemic, including gain-of-function research funding, mask and vaccine guidance, and the broader federal response that many conservatives argue caused lasting economic and social damage disproportionate to the actual threat. Supporters of the committee’s action argue that no witness — regardless of past government service or a prior pardon — should be able to simply refuse to answer legitimate congressional oversight questions without any consequence, and that letting this stand would set a troubling precedent for future oversight hearings of any administration. Whether the Justice Department ultimately decides to act on the referral remains to be seen, but the vote itself ensures the debate over pandemic accountability — and Fauci’s role in it — will remain a live political issue well into the fall. This story is developing.
Democrats Nominate Progressive Firebrand El-Sayed in Michigan, Setting Up Fall Clash With GOP’s Mike Rogers
Michigan Democrats have chosen progressive activist Abdul El-Sayed as their nominee for the state’s open U.S. Senate seat, rejecting the party establishment’s preferred candidate in favor of a further-left alternative — a result Republicans are already framing as a gift heading into what both parties agree is one of the most critical Senate races of the 2026 midterms. A Bruising, Narrow Win El-Sayed narrowly defeated Rep. Haley Stevens, D-Mich., in Tuesday’s primary, winning by roughly one percentage point after the race remained too close to call into Wednesday morning. The former Wayne County health director will now face Republican and former Rep. Mike Rogers in the general election for the seat being vacated by retiring Sen. Gary Peters — a race both parties view as essential to determining control of the chamber next year. El-Sayed’s win came despite a massive financial disadvantage. Stevens and her allies outspent El-Sayed and his supporters by nearly nine to one on advertising, according to ad-tracking firm AdImpact, with more than $30 million of that spending coming from the United Democracy Project, a super PAC affiliated with the American Israel Public Affairs Committee. Michigan Gov. Gretchen Whitmer also endorsed Stevens late in the race in what was widely seen as a last-ditch effort by the party establishment to block El-Sayed’s rise. The Most Progressive Wing Ascendant El-Sayed ran as an outspoken critic of both the Israeli government’s conduct in Gaza and continued U.S. military aid to Israel, positions that put him well to the left of most sitting Senate Democrats and drew sustained attacks from AIPAC-aligned groups throughout the campaign. “If you believe like me that rather than fund the genocide perpetrated by a foreign government, we better build schools right here in Grand Rapids, then we better put ourselves in democracy,” El-Sayed said at a recent campaign stop — rhetoric Republicans are already previewing as a preview of general-election attack ads to come. His win wasn’t an isolated data point. Michigan Democrats also nominated state Rep. Donavan McKinney, a self-described democratic socialist, over sitting Rep. Shri Thanedar in a competitive House primary the same night — suggesting Tuesday’s results reflect a broader leftward shift among Michigan’s Democratic primary electorate, not simply one unusually strong candidate. A Warning Sign for Democrats in a Swing State Michigan is a state Democrats effectively must hold to have any realistic path to a Senate majority in 2026, and Trump carried the state by roughly one point in the last presidential election, underscoring just how competitive the general electorate remains. Stevens, for her part, had attempted to cast El-Sayed as an extremist who would make things easier for Republicans, warning voters directly that the GOP was “propping up” his candidacy — a message that ultimately failed to overcome El-Sayed’s grassroots momentum and his argument that a nearly $65 million spending advantage represented exactly the kind of establishment influence voters were rejecting. Republicans see an opening. Rogers, who ran unopposed for the GOP nomination, now gets to run a general election campaign against a candidate who spent the primary sparring over U.S. aid to Israel and courting the most progressive wing of his party — a considerably different opponent than the more centrist, auto-industry-focused Stevens would have been. President Trump wasted little time weighing in publicly on the outcome, criticizing El-Sayed’s candidacy following the results. Democrats Try to Project Unity For his part, El-Sayed moved quickly to project a message of party unity following his narrow win, downplaying the closeness of the margin and telling supporters “we cannot wait to come together and win in November.” He also praised Stevens as a committed public servant, and Stevens herself offered her support to the nominee following the result, with Democratic Party leadership broadly coalescing behind him in the race’s immediate aftermath. Whether that unity holds through November remains to be seen. The race is expected to be one of the most closely watched and heavily funded Senate contests in the country, testing whether a candidate who won a Democratic primary by running to the left on foreign policy and criticizing his own party’s fundraising apparatus can still assemble a broad enough coalition to win a genuine swing state in a midterm year — a question that will likely shape how national Democrats think about candidate selection in competitive states well beyond this single race. This story is developing.
Blanche Vows DOJ Will Work to “Make Dobbs Permanent” in Every State, Drawing Praise From Pro-Life Groups and Fire From Democrats
Acting Attorney General Todd Blanche privately assured a group of anti-abortion activists this week that the Justice Department is working to ensure the Supreme Court’s Dobbs decision becomes a lasting, nationwide reality — a pledge that thrilled pro-life advocates who’ve grown impatient with the pace of federal action since Roe v. Wade was overturned, even as it drew immediate pushback from Democrats and some abortion-rights groups. What Blanche Told the Group Blanche made the comments on a call hosted by the White House Faith Office with Intercessors for America, a Christian advocacy organization, in a recording the group later posted publicly. “We’re working, hand in hand with HHS and the FDA and the White House and President Trump’s team, to get permanent solutions, so that the Dobbs decision becomes permanent in every single state,” Blanche told the group. He went on to project confidence about the ultimate outcome: “We don’t have complete victory yet, but we will have victory, and victory will be soon, and it will be permanent.” Blanche also signaled that the administration is preparing new restrictions on the prescription and mail delivery of abortion pills such as mifepristone, specifically targeting states that have adopted “shield laws” allowing doctors to prescribe abortion medication to patients living in other states. That approach isn’t new — Blanche had already committed to addressing mail-order abortion pill access during his own confirmation hearing, after being pressed on the issue by Sen. Katie Britt, R-Ala. A Win Pro-Life Advocates Have Been Waiting For For supporters of the pro-life movement, Blanche’s comments represent exactly the kind of sustained federal commitment they’d hoped to see following the Dobbs ruling, and confirmation that the administration intends to use the tools available to the Justice Department — not just leave the matter entirely to individual states — to protect unborn life nationwide. Advocates have grown frustrated in recent years watching abortion pill access expand dramatically through telehealth and mail-order prescriptions, which now account for the majority of abortions performed in the country; a DOJ-led effort to close that avenue, working alongside HHS and the FDA, is precisely the kind of coordinated executive action many pro-life leaders have been pushing for since Roe fell. Democrats and Some Republicans Push Back The comments landed differently on the other side of the aisle. Sen. Patty Murray, D-Wash., seized on the remarks ahead of Blanche’s Senate confirmation vote, telling colleagues that a vote for Blanche was effectively a vote for an attorney general who would “attack abortion rights in every state” — repeating Blanche’s own “every single state” language back at him. Sen. Tina Smith, D-Minn., made a similar argument, saying the private call revealed Blanche’s true intentions more clearly than his public confirmation testimony had. Notably, the pushback wasn’t confined entirely to Democrats. Sen. Susan Collins, R-Maine, a longtime supporter of abortion rights within the GOP conference, announced she would oppose Blanche’s nomination, citing both his private assurances to anti-abortion groups and a separate controversy over an IRS audit shield for the Trump family. Collins’ defection illustrates that Blanche’s posture on abortion pushes further than some in his own party are comfortable going, even within a Republican-controlled Senate broadly supportive of his nomination. The Larger Legal Strategy Reporting on the episode suggests the administration’s approach centers heavily on regulatory and legal action rather than legislation — a strategy that avoids the difficulty of passing a nationwide abortion law through a closely divided Congress. Anti-abortion groups have spent months pushing to resolve Louisiana v. FDA, a case that could restrict the mail-order mifepristone system through the courts rather than through a congressional vote. Supporters argue this is simply smart, available use of existing federal authority; critics argue it’s an attempt to achieve through executive and regulatory action what couldn’t be achieved through the ordinary legislative process — though of course, that critique cuts both ways depending on which policy area and which administration one is examining. Where Things Stand Blanche’s confirmation vote in the full Senate is expected soon after clearing the Judiciary Committee earlier this week by a 12-10 vote. Given the Republican majority in the chamber, he is likely to be confirmed even with Collins’ opposition, positioning him to begin implementing the policy priorities he outlined to Intercessors for America almost immediately upon taking the job on a permanent basis. Advocates on both sides of the abortion debate are likely to be watching closely for the administration’s next moves on mifepristone access and the shield-law states in the weeks following his confirmation. This story is developing.
Senate Confirms Dr. Erica Schwartz as CDC Director, Ending Yearlong Leadership Vacuum
The Senate voted Wednesday to confirm Dr. Erica Schwartz as director of the Centers for Disease Control and Prevention, giving the nation’s top public health agency its first permanent leader in nearly a year and closing out a turbulent stretch that saw two previous picks fail to make it through the confirmation process or survive on the job. A Steady Hand After a Rocky Stretch Schwartz was confirmed on a largely party-line 51-44 vote, with Sen. Tim Kaine, D-Va., the lone Democrat crossing over to support her. She becomes the 22nd director in the CDC’s history and the first Senate-confirmed leader of the agency in roughly a year, taking over from Dr. Jay Bhattacharya, who had been serving as acting director since February while also leading the National Institutes of Health. Her path to the job was notably smoother than her two predecessors. The administration’s first pick, former Rep. Dave Weldon, R-Fla., withdrew his own nomination after it became clear he lacked the votes, largely over concerns about his vaccine skepticism. His successor, Susan Monarez, was confirmed but fired less than a month later after what she described as a clash with HHS Secretary Robert F. Kennedy Jr. over his push to roll back childhood vaccine recommendations. A Resume Built on Public Health Experience Schwartz brings a substantial public health and military background to the role. A Brown University-trained physician, she served as deputy surgeon general during Trump’s first term and previously served as chief medical officer for the U.S. Coast Guard, in addition to time in the Navy and the Public Health Service Commissioned Corps. At 54, she also becomes the first Black woman to lead the CDC. President Trump nominated her in April, calling her “incredibly talented.” Notably, Schwartz represents something of a departure from earlier contenders the administration considered, who more closely toed the “Make America Healthy Again” line associated with Kennedy’s tenure at HHS. Her lengthy record overseeing vaccination programs and public health crisis response stands in contrast to the more skeptical posture that sank Weldon’s nomination. Questions About Independence Schwartz’s confirmation hearing last month put her in a difficult spot: reassuring senators that she’d bring scientific rigor to the job without appearing to publicly break with Kennedy, her eventual boss. She told the Senate HELP Committee she accepts there is “overwhelming evidence” that vaccines don’t cause autism, but stopped short of committing to remove a CDC webpage — updated last November — that critics say downplays that evidence. When Sen. Bill Cassidy, R-La., the committee’s chairman, pressed her on whether she’d challenge Kennedy directly, she described handling disagreements the way she had in the military — through private conversations with superiors rather than public confrontation. That answer didn’t satisfy everyone. Sen. Bernie Sanders, I-Vt., the committee’s ranking member, voted against her both in committee and on the floor, saying he was impressed by her credentials but didn’t believe she was prepared to stand up to what he characterized as false statements on vaccines coming from Kennedy’s HHS. “I think the American people are owed better than what President Trump has nominated,” Sanders said. Others in the public health community took a more measured view of her approach. Dr. Georges Benjamin, CEO of the American Public Health Association, suggested her measured public posture during confirmation was a pragmatic choice rather than a red flag. “Public health people in these positions often have to manage through influence,” Benjamin said. “You don’t get influence by disagreeing with your boss publicly before you even get the job.” The Challenges Waiting for Her Schwartz inherits an agency that has been significantly reshaped over the past year and a half. The CDC has lost more than a quarter of its workforce through layoffs and resignations amid broader restructuring at HHS, and morale has reportedly suffered as a result. She also takes over amid two active public health challenges: the nation’s worst measles outbreak since before elimination was declared in 2000, and a growing cyclosporiasis outbreak that has already been linked to at least two deaths in Michigan. Benjamin, among others, argues the agency’s credibility has taken a real hit during the period of acting leadership and restructuring. “The CDC’s influence has diminished dramatically since they’ve taken over,” he said. “You have to second-guess and verify what is said. We never had to do that before.” Supporters of the administration’s broader health agenda counter that a leaner, more accountable CDC — one less resistant to oversight from elected officials — is a feature of the reform effort, not a flaw, and that Schwartz’s credentials make her well-positioned to restore both competence and public trust to the role regardless of the political noise surrounding her confirmation. What’s Next Schwartz is expected to be sworn in within the next several days. Her first major tests will likely come quickly, given the ongoing measles situation and the upcoming August meeting of the newly reconstituted U.S. Preventive Services Task Force — both flashpoints that will offer an early read on how independently she’s able to operate within Kennedy’s HHS. This story is developing.
Iran and Oman Agree on Hormuz Shipping Coordinates, But Tehran Makes Clear the Strait Isn’t Reopening Yet
Iran and Oman announced Wednesday that they’ve agreed on the geographic coordinates for a new commercial shipping route through the Strait of Hormuz, a step toward de-escalation that comes even as Tehran insists it has no intention of fully reopening the critical waterway anytime soon — a reminder that the diplomatic progress touted by U.S. officials in recent days remains far more fragile than the headlines might suggest. What Was Actually Agreed Iranian Foreign Ministry spokesperson Esmaeil Baghaei told reporters that after roughly two months of negotiations, the two countries have settled on coordinates for a proposed shipping route, and that a joint statement covering the technical, legal, security, and environmental details of the arrangement is now in its final stages of drafting. “The geographical coordinates of the route proposed by the two sides have been agreed upon,” Baghaei said, adding the caveat that the joint statement would only move forward “provided that certain third parties do not obstruct the process” — a clear reference to the United States. Iran’s deputy foreign minister for legal and international affairs, Kazem Gharibabadi, told state news agency IRNA that the two countries have reached understanding on “almost all” outstanding issues in the negotiation. The Catch: Iran Still Wants the US Blockade Lifted First Despite the apparent breakthrough on coordinates, Baghaei was explicit that an agreement with Oman alone won’t be enough to make the strait safe for shipping. “An understanding with Oman cannot, in itself, mean that the strait has become safe for passing vessels, because the factors creating insecurity in the Strait of Hormuz — particularly the U.S. naval blockade and other actions against Iran and its interests — remain in place,” he said. That’s a significant condition. Reuters reported that the proposed arrangement would give Tehran control over ships entering the Gulf through the strait — described by sources as one of the biggest concessions to Iran since the war began — while regional officials cautioned that important details still needed to be finalized despite President Trump’s recent public optimism that a deal reopening the strait was close at hand. How We Got Here Iran effectively closed the Strait of Hormuz in March in response to the U.S. and Israeli strikes that launched the war in late February, and its forces have repeatedly threatened commercial vessels attempting to transit the waterway with drones, missiles, small boats, and mines ever since. An earlier ceasefire framework, the Islamabad Memorandum of Understanding, collapsed in July, triggering a fresh wave of strikes and reigniting the standoff over the strait that has disrupted roughly 20% of the world’s oil and liquefied natural gas exports and pushed global energy prices higher for months. At its narrowest point, the strait is just 21 miles wide, meaning any agreement over shipping lanes and territorial control carries outsized strategic weight — there’s essentially no room for a truly neutral international shipping lane if both countries insist on standard 12-mile territorial waters. Reading the Administration’s Position Trump administration officials have been eager to characterize the negotiations as evidence that sustained American pressure is finally working. Treasury Secretary Scott Bessent said earlier this week that a deal could come within days, and noted that vessel traffic has already picked back up despite the continued uncertainty. Whether that optimism proves justified will depend heavily on what happens next: Iran’s insistence on tying any final resolution to an end of the U.S. naval presence in the region suggests Tehran still believes it holds real leverage, even after months of American and Israeli strikes on its military and nuclear infrastructure. Supporters of the administration’s approach argue that extracting even partial concessions from Iran — a country that had effectively shut down a fifth of the world’s oil shipping for months — represents real progress from a position of strength, and that Tehran’s public hedging is standard negotiating posture rather than a sign the pressure campaign has stalled. Skeptics counter that a deal requiring the U.S. to lift its naval blockade in exchange for Iranian control over Gulf-bound shipping lanes would hand Tehran a durable strategic win, not a defeat, regardless of how the administration chooses to frame it. What Comes Next Officials on both sides say the joint statement between Iran and Oman is nearly finished, but its release — and any broader resolution to the shipping standoff — still hinges on decisions well above either country’s negotiating teams. Reports suggest the broader framework may also require sign-off from Iran’s Supreme Leader before anything becomes final. In the meantime, the war itself continues, with American and Israeli strikes ongoing and no comprehensive ceasefire yet in place covering anything beyond the narrow question of Gulf shipping routes. This story is developing.
US Measles Cases Hit 30-Year High, But CDC Official Says Losing Elimination Status “Not Really” a Concern
The United States has recorded more measles cases in 2026 than in any full year since the disease was declared eliminated in 2000, putting the country’s quarter-century-old elimination status at real risk — but a top CDC official says the milestone, if it happens, isn’t the alarming development some public health voices are making it out to be. The Numbers Behind the Headlines As of July 30, the CDC had confirmed 2,371 measles cases nationwide in 2026, already surpassing the 2,289 cases recorded for all of 2025 — itself the highest annual total since 1991. The case count spans 37 separate outbreaks so far this year, with active clusters currently being tracked in states including Virginia, Pennsylvania, and Utah. Johns Hopkins researcher William Moss noted that hitting this milestone so early in the year, with five months still remaining, is a particularly striking sign of how persistent this year’s spread has been. The largest single outbreak of the year unfolded in South Carolina’s Spartanburg County, which saw the biggest measles outbreak the U.S. has experienced in decades before state health officials declared it over in late April, with just under 1,000 total cases. Utah has since emerged as the new center of concern, with more than 500 confirmed cases so far in 2026 alone. What “Elimination Status” Actually Means Measles elimination doesn’t mean the disease has vanished from American soil entirely — it’s a technical designation meaning the virus hasn’t achieved continuous, uninterrupted domestic transmission for more than 12 months. The U.S. earned that status in 2000 after decades of successful vaccination campaigns nearly wiped the virus out. If health officials determine that this year’s outbreaks are genetically and epidemiologically linked to a chain of transmission stretching back more than a year — potentially connecting back to an outbreak that began in West Texas in January 2025 — the country could officially lose the designation for the first time in a generation. That determination isn’t made by the CDC alone. An external panel called the Measles, Rubella, and Congenital Rubella Syndrome Elimination Regional Verification Commission, operating under the Pan American Health Organization, is responsible for the final call, relying in part on genetic sequencing data that CDC scientists are still working to compile and publish. A CDC Official Pushes Back on the Alarm Not everyone in the federal health apparatus is treating the potential loss of elimination status as a five-alarm fire. CDC Principal Deputy Director Dr. Ralph Abraham, a former Louisiana surgeon general who previously scaled back vaccine promotion efforts in that state, told reporters at a briefing that losing the designation wouldn’t fundamentally change how the country handles the disease. “Losing elimination status … does not mean that the measles would be widespread, nor would it alter any key measles elimination strategies,” Abraham said, while adding that he continues to personally support vaccination as the most effective tool against the disease — even as he also emphasized the importance of personal freedom in health decisions. Abraham also pushed back on claims that ongoing outbreaks in different states are necessarily connected, arguing that continuous transmission between the various clusters “has not been proved” and shouldn’t be assumed just because outbreaks are occurring simultaneously in multiple regions. The Vaccination Rate Debate Public health researchers point to declining childhood MMR vaccination rates as the central driver behind the resurgence. National kindergarten MMR coverage has slipped to around 92.5%, below the roughly 95% threshold considered necessary to maintain herd immunity against a virus as contagious as measles — the CDC estimates that if one infected person is in a room with unprotected people, up to nine out of ten will catch it. The vast majority of this year’s cases, more than 95%, have occurred in people who were unvaccinated or whose vaccination status was unknown. Some researchers argue the stakes of continued vaccination decline are significant: one estimate suggests that just a single percentage-point drop in the childhood MMR vaccination rate could translate into roughly 17,000 additional measles cases, 4,000 hospitalizations, and 36 preventable deaths nationally each year. Three deaths and 243 hospitalizations were attributed to last year’s outbreaks alone, with about a quarter of 2025’s cases occurring in children under five. Personal Choice Versus Public Health The debate over how aggressively to respond has become something of a proxy fight in the broader national conversation about vaccine mandates, parental rights, and the proper role of government in personal health decisions — a conversation Health and Human Services Secretary Robert F. Kennedy Jr. has placed at the center of his tenure leading the department. Supporters of the administration’s more hands-off approach argue that decisions about vaccination ultimately belong to individual families, not federal health bureaucrats, and that framing a technical elimination-status change as a public health emergency risks stoking unnecessary panic over a disease that, while serious, remains treatable and preventable for those who choose vaccination. Critics, including some public health researchers, counter that measles’ extraordinary contagiousness means individual choices carry real consequences for the broader community, particularly for infants too young to be vaccinated and people with compromised immune systems who can’t be vaccinated even if they wanted to be. Dr. Dave Chokshi, chair of the Common Health Coalition, framed it directly: “Vaccination is one of the most powerful investments we can make for the health of our children, but when we fail to maintain high vaccination rates, we all pay the price.” The International Backdrop The U.S. wouldn’t be alone if it loses its elimination status. Canada lost its own measles-free designation in late 2025, and the United Kingdom and several other European countries have also lost their elimination status in recent years amid similar declines in vaccination coverage — suggesting the trend driving America’s numbers is part of a broader pattern playing out across the developed world, rather than an isolated domestic failure. What Happens Next CDC scientists continue working with state and international partners to complete the genetic sequencing analysis that will ultimately determine whether this year’s…
25 Blue States Sue to Block Trump’s Latest Tariffs, Setting Up Third Round of Legal Battles
A coalition of 25 Democratic-led states filed suit against the Trump administration this week over its newest round of tariffs, marking the third time in less than two years that blue-state attorneys general have gone to court to challenge the president’s trade agenda — and setting up yet another high-stakes legal showdown over just how far a president’s tariff authority actually extends. What the Lawsuit Targets The lawsuit, filed Monday in the U.S. Court of International Trade, takes aim at tariffs the administration announced on July 23, imposing duties of 10% to 12.5% on goods from more than 80 trading partners, including the European Union. The stated justification for the new levies was different from the administration’s earlier tariff push: rather than citing a national trade deficit emergency, the U.S. Trade Representative’s office said the tariffs were necessary because the targeted countries had failed to adequately ban and enforce prohibitions on imports made with forced labor. The states argue that rationale doesn’t hold up. The lawsuit, filed under Section 301 of the Trade Act of 1974, alleges the tariff action was “arbitrary, capricious, and contrary to law,” and claims that public comments and testimony gathered by the USTR actually undercut the forced-labor justification rather than support it. New York Attorney General Letitia James, who has led the multistate coalition through all three rounds of tariff litigation, didn’t hold back in her public response. “After losing at the Supreme Court, the administration is once again trying to illegally raise taxes on families and businesses with a new round of tariffs,” James wrote. “The president doesn’t have the power to impose sweeping tariffs.” A Familiar Legal Fight, Third Time Around This is not new legal territory for either side. The same coalition of states first sued the administration back in April 2025, arguing that Trump’s use of the International Emergency Economic Powers Act, or IEEPA, to impose sweeping “Liberation Day” tariffs on nearly every country in the world was unlawful. That argument found real traction: in February, the Supreme Court agreed, ruling that IEEPA simply doesn’t authorize the president to impose tariffs of that scope, forcing the administration to issue refunds to importers who had already paid the disputed duties. Rather than abandon its tariff strategy after that defeat, the administration pivoted to a different legal justification. It invoked Section 122 of the Trade Act of 1974 to impose temporary 10% tariffs on most imported products, arguing that statute gave it the necessary authority. States sued again, and in May, the U.S. Court of International Trade ruled that those tariffs, too, were unlawful. Now, with the clock having run out on that temporary tariff regime, the administration has turned to yet a third legal basis — Section 301 — to justify its latest round of duties. Unlike the two previous statutes at issue, Section 301 has a somewhat sturdier legal track record: Trump used it during his first term to impose significant tariffs on China, and those survived court challenges at the time. Whether that precedent will hold up against this newest and much broader application, covering dozens of countries rather than a single trading partner, is now squarely in the hands of the Court of International Trade. The States Involved Joining New York in the latest lawsuit are Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Illinois, Kentucky, Massachusetts, Maryland, Maine, Michigan, Minnesota, Nevada, New Jersey, New Mexico, North Carolina, Oregon, Pennsylvania, Rhode Island, Virginia, Vermont, Washington, and Wisconsin — a coalition made up entirely of Democratic attorneys general, continuing the partisan pattern that’s defined all three rounds of tariff litigation so far. The Administration’s Defense White House officials are standing firmly behind the legal basis for the new tariffs. White House spokesperson Kush Desai defended the administration’s approach in a statement, arguing that “the United States is using its lawful authority to obtain the elimination of unreasonable acts, policies, and practices that burden U.S. commerce.” Desai further argued that Section 301 tariffs have “proven to be a legally durable tool since the president’s first term, and they remain so now” — a direct reference to the tool’s successful track record surviving legal challenges during Trump’s earlier term in office. Supporters of the administration’s broader trade strategy argue that repeated legal setbacks on specific statutory grounds don’t undermine the underlying policy goal: using tariffs as leverage to address unfair trade practices, protect American manufacturing, and hold foreign governments accountable for labor and environmental practices that put U.S. businesses at a competitive disadvantage. From that view, the administration’s willingness to pursue tariff authority through multiple different legal avenues — rather than abandoning the strategy after the IEEPA and Section 122 defeats — reflects persistence in pursuing a policy priority that voters supported at the ballot box, not a legal end-run around the courts. Why This Round May Be Different There’s an argument that the forced-labor justification behind these newest tariffs gives the administration firmer legal footing than its previous attempts. Unlike the emergency-powers rationale that the Supreme Court rejected, Section 301 is specifically designed by Congress to let the executive branch respond to unfair trade practices identified through a formal investigative process — precisely the kind of process the USTR says it followed here. Whether that process holds up to judicial scrutiny, particularly the states’ claim that the USTR’s own gathered evidence undercuts its stated rationale, will be the central question as the case moves forward. What Happens Next The lawsuit asks the Court of International Trade to both block enforcement of the new tariffs going forward and order refunds for duties already collected under the Section 301 action — the same remedy states won in their first successful challenge earlier this year. Given the pattern of the previous two cases, expect an expedited briefing schedule and likely appeals regardless of which side prevails at the trial court level, keeping the fate of a significant chunk of the administration’s trade policy tied up in litigation for months to come. For American businesses and…
Tadej Pogačar Wins Historic Fifth Tour de France, Joining Cycling’s Greatest Ever
Slovenian cyclist Tadej Pogačar completed one of the most dominant runs in modern cycling history this week, capturing his fifth Tour de France title and becoming just the fifth rider ever to win the race three years running, joining an elite club that includes some of the sport’s most legendary names. A Dominant Three Weeks Pogačar entered the race’s final stage in Paris with a commanding seven-minute lead, all but guaranteeing the win before the peloton even hit the Champs-Élysées. His total time across the grueling three-week race — which spanned more than 3,321 kilometers and 54,450 meters of elevation gain, starting in Barcelona — came in at 73 hours, 56 minutes, and 26 seconds, nearly six and a half minutes faster than his nearest competitor, Belgium’s Remco Evenepoel. Dutch rider Mathieu van der Poel won the final stage itself by the thinnest of margins, edging out Pogačar in a two-man sprint after the pair broke away from the pack late in the race — but the stage win did nothing to change the overall outcome, which had been effectively sealed days earlier. Joining Cycling Royalty With this fifth overall title, Pogačar becomes just the fifth cyclist in history to win the Tour de France three years in a row, joining a group that includes Jacques Anquetil, Eddy Merckx, Bernard Hinault, and Miguel Induráin — legendary names in the sport’s history. He’s the first rider to pull off three straight wins since Chris Froome accomplished the feat from 2015 to 2018. “Unbelievable,” Pogačar told reporters after crossing the finish line, thanking his fans and team for the support that carried him through another grueling campaign. A Race Marked by More Than Racing This year’s edition wasn’t without disruption. The final stage’s route was shortened after security and police resources originally assigned to the race were reassigned to help battle wildfires burning in southwest France, a reminder of how extreme summer conditions across Europe are increasingly bleeding into major sporting events. Even with the shortened course, the finale delivered one of the more dramatic sprint finishes of the tournament, capping off a Tour that once again cemented Pogačar’s place among the sport’s all-time greats. This story is developing.
Kennedy Set to Overhaul Influential Panel That Decides Free Cancer Screenings for Millions
HHS Secretary Robert F. Kennedy Jr. is preparing to name as many as eight new members to the U.S. Preventive Services Task Force, the influential and little-known federal panel that determines which preventive medical services — from mammograms to colonoscopies to cancer screenings — insurers must cover for free, with the newly reshaped panel set to hold its first meeting in 17 months this August. A Long-Overdue Shake-Up, Supporters Say Kennedy has repeatedly criticized the task force’s past performance, describing it at one point as “lackadaisical,” and has moved to remake the panel after blocking it from meeting on multiple occasions, declining to replace members whose terms expired, and removing its vice chairs in May. The task force, normally composed of 16 experts, has shrunk by half in recent months as Kennedy has worked to reconstitute it with new leadership. Notably, the incoming selection process is reportedly favoring specialists over the primary care physicians who have traditionally filled these roles — a departure supporters say could bring fresh, more clinically focused perspectives to a panel that plays an outsized role in American healthcare. What the Panel Actually Does The task force’s recommendations carry real financial weight for patients. Services that receive the panel’s highest grades — “A” or “B” — must be covered by most private insurers and state Medicaid expansion programs without any copays or deductibles. That includes widely used preventive services like mammograms, colonoscopies, and pap tests, meaning changes in the panel’s composition and priorities could eventually ripple out to affect coverage decisions for millions of Americans. Questions About the Process The overhaul hasn’t been without scrutiny. Former task force members have said the process for selecting new members has been less transparent than in years past, and HHS has not detailed publicly why several previously completed recommendations have not yet been released. HHS says the August meeting was delayed due to an unusually high volume of nominations for the open seats, requiring more time to properly vet and onboard the incoming members. Supporters of Kennedy’s approach argue that an independent-in-name-only panel benefits from new energy and accountability, especially given how directly its decisions affect what Americans pay out of pocket for basic preventive care, while critics continue to press for more transparency around how the new members are being chosen and what direction they intend to take the panel in. This story is developing.